REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA

Repurposing of FDA approved compounds to inhibit OSM/OSMR signaling in glioblastoma OSM/OSMR signalling is important in glioblastoma, yet specific inhibitors to suppress this signaling pathway remain to be explored. Here we conducted HTS screening of FDA approved compounds to identify lead compounds...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotfipour, Farzaneh, Jahani-Asl, Arezu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337565/
http://dx.doi.org/10.1093/noajnl/vdad071.044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337565/
http://dx.doi.org/10.1093/noajnl/vdad071.044

Ejemplares similares